Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial)

Jürgen Krauter; Walter Fiedler; Richard F. Schlenk; Peter Paschka; Felicitas Thol; Michael Lübbert; Mohammed Wattad; Mareike Verbeek; Christian Könecke; Barbara Neuhaus; Armin Papkalla; Maxim Kebenko; Melanie Janning; Konstanze Döhner; Verena I. Gaidzik; Heiko Becker; Christine Greil; Peter Reimer; Katharina S. Götze; Hartmut Döhner; Arnold Ganser; Michael Heuser

doi:10.1111/bjh.15546

Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial)

Jürgen Krauter^*, Walter Fiedler, Richard F. Schlenk, Peter Paschka, Felicitas Thol, Michael Lübbert, Mohammed Wattad, Mareike Verbeek, Christian Könecke, Barbara Neuhaus, Armin Papkalla, Maxim Kebenko, Melanie Janning, Konstanze Döhner, Verena I. Gaidzik, Heiko Becker, Christine Greil, Peter Reimer, Katharina S. Götze, Hartmut DöhnerArnold Ganser, Michael Heuser

^*Korrespondierende/r Autor/-in für diese Arbeit

Klinik für Hämatologie und Onkologie

2 Zitate (Scopus)

Abstract

This open-label, multicentre phase I/II study determined the maximum tolerated dose (MTD), safety and efficacy of clofarabine administered with cytarabine and idarubicin in newly diagnosed acute myeloid leukaemia (AML) patients lacking favourable genetic aberrations. The MTD was 30 mg/m² clofarabine for patients below and above 60 years. The most frequently reported grade 3–4 non-haematological adverse events were infectious and gastrointestinal toxicities. Complete remission (CR)/CR with incomplete recovery rate was 67%. Allogeneic haematopoietic cell transplantation in first remission was feasible in a high proportion of younger AML patients and probably contributed to the favourable outcome compared to historical controls.

Originalsprache	Englisch
Zeitschrift	British Journal of Haematology
Jahrgang	183
Ausgabenummer	2
Seiten (von - bis)	235-241
Seitenumfang	7
ISSN	0007-1048
DOIs	https://doi.org/10.1111/bjh.15546
Publikationsstatus	Veröffentlicht - 10.2018

Zugriff auf Dokument

10.1111/bjh.15546

Andere Dateien und Links

Link to publication in Scopus

Fingerprint

Untersuchen Sie die Forschungsthemen von „Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial)“. Zusammen bilden sie einen einzigartigen Fingerprint.

Zitieren

Krauter, J., Fiedler, W., Schlenk, R. F., Paschka, P., Thol, F., Lübbert, M., Wattad, M., Verbeek, M., Könecke, C., Neuhaus, B., Papkalla, A., Kebenko, M., Janning, M., Döhner, K., Gaidzik, V. I., Becker, H., Greil, C., Reimer, P., Götze, K. S., ... Heuser, M. (2018). Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial). British Journal of Haematology, 183(2), 235-241. https://doi.org/10.1111/bjh.15546

@article{d1698c6364604260bfe812071826e112,

title = "Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial)",

abstract = "This open-label, multicentre phase I/II study determined the maximum tolerated dose (MTD), safety and efficacy of clofarabine administered with cytarabine and idarubicin in newly diagnosed acute myeloid leukaemia (AML) patients lacking favourable genetic aberrations. The MTD was 30 mg/m2 clofarabine for patients below and above 60 years. The most frequently reported grade 3–4 non-haematological adverse events were infectious and gastrointestinal toxicities. Complete remission (CR)/CR with incomplete recovery rate was 67%. Allogeneic haematopoietic cell transplantation in first remission was feasible in a high proportion of younger AML patients and probably contributed to the favourable outcome compared to historical controls.",

author = "J{\"u}rgen Krauter and Walter Fiedler and Schlenk, {Richard F.} and Peter Paschka and Felicitas Thol and Michael L{\"u}bbert and Mohammed Wattad and Mareike Verbeek and Christian K{\"o}necke and Barbara Neuhaus and Armin Papkalla and Maxim Kebenko and Melanie Janning and Konstanze D{\"o}hner and Gaidzik, {Verena I.} and Heiko Becker and Christine Greil and Peter Reimer and G{\"o}tze, {Katharina S.} and Hartmut D{\"o}hner and Arnold Ganser and Michael Heuser",

note = "Publisher Copyright: {\textcopyright} 2018 British Society for Haematology and John Wiley & Sons Ltd",

year = "2018",

month = oct,

doi = "10.1111/bjh.15546",

language = "English",

volume = "183",

pages = "235--241",

journal = "British Journal of Haematology",

issn = "0007-1048",

number = "2",

}

Krauter, J, Fiedler, W, Schlenk, RF, Paschka, P, Thol, F, Lübbert, M, Wattad, M, Verbeek, M, Könecke, C, Neuhaus, B, Papkalla, A, Kebenko, M, Janning, M, Döhner, K, Gaidzik, VI, Becker, H, Greil, C, Reimer, P, Götze, KS, Döhner, H, Ganser, A & Heuser, M 2018, 'Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial)', British Journal of Haematology, Jg. 183, Nr. 2, S. 235-241. https://doi.org/10.1111/bjh.15546

Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial). / Krauter, Jürgen; Fiedler, Walter; Schlenk, Richard F. et al.
in: British Journal of Haematology, Jahrgang 183, Nr. 2, 10.2018, S. 235-241.

Publikation: Beiträge in Fachzeitschriften › Zeitschriftenaufsätze › Forschung › Begutachtung

TY - JOUR

T1 - Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial)

AU - Krauter, Jürgen

AU - Fiedler, Walter

AU - Schlenk, Richard F.

AU - Paschka, Peter

AU - Thol, Felicitas

AU - Lübbert, Michael

AU - Wattad, Mohammed

AU - Verbeek, Mareike

AU - Könecke, Christian

AU - Neuhaus, Barbara

AU - Papkalla, Armin

AU - Kebenko, Maxim

AU - Janning, Melanie

AU - Döhner, Konstanze

AU - Gaidzik, Verena I.

AU - Becker, Heiko

AU - Greil, Christine

AU - Reimer, Peter

AU - Götze, Katharina S.

AU - Döhner, Hartmut

AU - Ganser, Arnold

AU - Heuser, Michael

PY - 2018/10

Y1 - 2018/10

N2 - This open-label, multicentre phase I/II study determined the maximum tolerated dose (MTD), safety and efficacy of clofarabine administered with cytarabine and idarubicin in newly diagnosed acute myeloid leukaemia (AML) patients lacking favourable genetic aberrations. The MTD was 30 mg/m2 clofarabine for patients below and above 60 years. The most frequently reported grade 3–4 non-haematological adverse events were infectious and gastrointestinal toxicities. Complete remission (CR)/CR with incomplete recovery rate was 67%. Allogeneic haematopoietic cell transplantation in first remission was feasible in a high proportion of younger AML patients and probably contributed to the favourable outcome compared to historical controls.

AB - This open-label, multicentre phase I/II study determined the maximum tolerated dose (MTD), safety and efficacy of clofarabine administered with cytarabine and idarubicin in newly diagnosed acute myeloid leukaemia (AML) patients lacking favourable genetic aberrations. The MTD was 30 mg/m2 clofarabine for patients below and above 60 years. The most frequently reported grade 3–4 non-haematological adverse events were infectious and gastrointestinal toxicities. Complete remission (CR)/CR with incomplete recovery rate was 67%. Allogeneic haematopoietic cell transplantation in first remission was feasible in a high proportion of younger AML patients and probably contributed to the favourable outcome compared to historical controls.

UR - http://www.scopus.com/inward/record.url?scp=85055637687&partnerID=8YFLogxK

U2 - 10.1111/bjh.15546

DO - 10.1111/bjh.15546

M3 - Journal articles

C2 - 30378121

AN - SCOPUS:85055637687

SN - 0007-1048

VL - 183

SP - 235

EP - 241

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 2

ER -